clinical trial · NCT05511922
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Hereditary AngioedemaKVD900 600 mgDrug: KVD900 300 mg
brief summary
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
started
Oct 24, 2022
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Jul 18, 2025
official title
A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol